MIACH Orthopaedics, a bioengineered surgical implant company, completed $22.5 million in financing.
Biologics
UC San Diego researchers derived spinal cord neural stem cells from human pluripotent stem cells transplanted into a rat model with spinal cord injury, according to a study in Nature Methods.
University of Toledo (Ohio) researchers developed a smart injectable calcium phosphate bone cement for orthopedic and spinal fusion applications. The smart CaP compositions were biocompatible, according to a study in Materials.
Best in Class Care entered an agreement with Regenexx to reduce high-cost musculoskeletal surgeries and accelerate employers' ability to directly contract with its network of providers.
The Seattle Regenerative Medicine Center opened a new location in Bellevue, Wash.
Advertisement
Baxter International received FDA clearance for its Actifuse Flow bone graft substitute.
Mark Mikhael, MD, is studying the use of proteins from donor stem cells in spinal fusion surgery, Chicago Health reports.
Market analysts predict the spine biologics market will top $2.6 billion by 2022, growing at a 4.4 percent compound annual growth rate, according to a Market Research Engine report.
SpinalCyte received a U.S. patent for its cartilage repair technology using an in vivo bioreactor.
While the use of biologics in spine surgery is still emerging, more spine surgeons are gaining exposure to the field as new clinical trials and noninvasive treatments are born.